Transcriptional signatures and immune cell infiltrates associated with immune activation distinguish patients with glioblastoma who initially respond to immune checkpoint blockade from those who do not.
References
Ostrom, Q. T. et al. Neuro. Oncol. 20, iv1–iv86 (2018).
Nam, J. Y. & de Groot, J. F. J. Oncol. Pract. 13, 629–638 (2017).
Chiocca, E. A., Nassiri, F., Wang, J., Peruzzi, P. & Zadeh, G. Neuro. Oncol. 21, 14–25 (2019).
Kamiya-Matsuoka, C. & Gilbert, M. R. CNS Oncol. 4, 91–104 (2015).
Dyck, L. & Mills, K. H. G. Eur. J. Immunol. 47, 765–779 (2017).
Zhao, J. Nat. Med. https://doi.org/10.1038/s41591-019-0349-y (2019).
Mooney, K. L. et al. J. Clin. Neurosci. 34, 1–5 (2016).
Schalper, K. A. Nat. Med. https://doi.org/10.1038/s41591-018-0339-5 (2019).
Cloughsey, T. F. Nat. Med. https://doi.org/10.1038/s41591-018-0337-7 (2019).
Hegi, M. E. et al. N. Engl. J. Med. 352, 997–1003 (2005).
Yan, H. et al. N. Engl. J. Med. 360, 765–773 (2009).
Keskin, D. B. et al. Nature 565, 234–239 (2019).
Kurz, S. C. & Wen, P. Y. Curr. Treat. Options Neurol. 20, 14 (2018).
Thomas, A. A. et al. Cancer Immunol. Immunother. 66, 379–389 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.A.C is currently an advisor to Advantagene Inc., Alcyone Biosciences, Insightec, Inc., Sigilon Therepeutics and DNAtrix Inc. and has equity interest in DNAtrix; he has also advised Oncorus, Merck, Tocagen, Ziopharm, Stemgen, NanoTx., Ziopharm Oncology, Cerebral Therapeutics, Genenta, Merck, Janssen, Karcinolysis, and Shanaghai Biotech. He has received research support from the National Institutes of Health, the US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV1.
Rights and permissions
About this article
Cite this article
Ito, H., Nakashima, H. & Chiocca, E.A. Molecular responses to immune checkpoint blockade in glioblastoma. Nat Med 25, 359–361 (2019). https://doi.org/10.1038/s41591-019-0385-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0385-7
- Springer Nature America, Inc.
This article is cited by
-
Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas
Scientific Reports (2022)
-
Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature
BMC Cancer (2021)
-
Multi-responsive nanofibers composite gel for local drug delivery to inhibit recurrence of glioma after operation
Journal of Nanobiotechnology (2021)
-
The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment
Journal of Molecular Neuroscience (2020)